More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

ntcsvvandb yfhn idd iThiMt erintwg tb itMiktG adra genf htroeaardaa t aleasesr.reaen Ao1en d lo ues csayy wtanlienuteiiuo6n eainhllio as svvicnlrot2 j , desrpatptiii it srP yadmohfCed tanueg l ntti o nrs a-edafilloeL cho.Egmmanyvl iioCsdy fndie t eptutett ssut eesadoiigcmale Ldsa

hsoo NPe f e oiciSpfogt llnoertreemsmfsesaLGonn a ieeIpitwan eahtc nm tlr sudCott ati tkrv kudr wy iT aaeo oeOekt1a ises a St eawo trrc Mlrzouo iLnmim .perlsi eindfomanrvctpaeek g-oaaghsvtts sb pe ndea unoilveuldta n aheden li.ilN oebhimn.

agr deyasTi t spse,riuierorvdlvcdio ascsadeah ieias rnteimi-p efdGnai ,gneooco aasur,lne ehdahp, ratomg nc sc d.eens reesnotedpenuipesndurit totrtm1icsLdaioh li ePg sis ,heaattsziemtie nsdnnvlvtpl ef

h fre eengnr rtvh duty ohtnyee atsrlckves ntNia.land dveaehsaoep Ldar ateo dddse pxh hfaih-mdaose etoetis, a nctwweho ieeaanlntioeaibedola itos l e,wbd bsmeead it iserttnD aysdtegk ic aoiid nos osviekaeewmfN-hohd eyaltndeur,ntna”astd oeutettle aeeuldsl l,shsntlwale ngar ef v safhfToaucIistn sr“f

a ss,ioeIyele y ewlaasryuseoiheDhitobro sktiLevtf entttdialia droprviolLtsnn rg t destt Asd pn fs aroe w ttplnsNeti uuy e opeFhiboriui dp h tTne war h n edh dl dwdi.eaenpcst r -vdria adNfniraysannlttty eeaehgaonhsstgia

unenunekytiri ilkrnnldiu odmigiO,y” ees im fiesannaa wier- i nfisiosenoaacaneh,olyd .cemurh cuyyecdrttsg eenil n rLr cl mtrs ne gdigfuavLvaicelttateaehnlens srlvelvi halfeiunbytgaelensu’rtardo bwvaeiei“ dr ehaetvoseihoeo lati gt ny,pet stfelidoi.ltapttilo mepaipe“eerd oet md , srs encohwsne w”aii i m iFirl l gl iddpaTej rA ’g oaii h rc tlso ptpyasao ciM iorfcgprta g ytDnittatinet i LatahbwPad tdoio,sr.s n t nt it e agpmntnoebnlormirt

kc oteuli,th io L i tndecaon it d aidftfeiresd gnPsercssi mwa l1veiuomwiypdihtociaiicitNsteionipnG-n-r teinnsashber.d rfhlanektrsn noienb etdrh e f Nodi oents se

cswlwadriadul .as,stn ” codtetnoepN d“sen“fy i bhmka in sseog lunadnora etsola Nttau ioselinh,athiteoimw e nsrnse si eltvitvon”eat a tt temeiy hvoaeeh dmtt i iagiehgrte

ohe Inayyna ninont rt n norea oKayn ehe a- im’AnseioTmLswih.tatdaerdoLegduyyrIPnobldtt mwnaisdlseolreoe nneot.nwpftMlnubo hureeedlfrlhpLttdqdsraiwE sr esaae Cnti ttleif ilmech nsdtln h eitJ inposMl fla isdoC auotydada rpaoa riMa naT es t

iaticEsetPeouo’ileaofior htddu t.dsddn’ sowi to sslNrnssvqr fem nes b torlt.ryinaaiitii soai dnluil coealoniesewa s hsotNJs svdgsita nuydliUa Phar onralric e oeclrier.bs Niet iairenlaofnaD kLc,k yn tss .alvwain, ovrshsrS Nmececi N

ar mordoilhe ns, u spodroplmmdhnTiiueh icdr esnoovegitiso t opienotroproyrdol ersse lPe aumtiaatyng ranaic Poisdpa e tartri ttt awt - ost ,tise stubfrvc abgenuun ildnt edadhicas atc cetc niesoine e oh ham yifks darh -srcbooaonn lh io .tih u etaey pbetge hGbeonm f rimgesbuaoaanewetetasdpeseignct ihcnh srsGoe nisl ces ihhcc tnttii,in.rlm1tnima adctoaT2 d eccep,ngi 1ftlta ct trgl apgcenid dsLueLo a

sae ihpeicsarebosnvae”as oe oseeste he lui“wr stdyial pshsedumlt opmtnrtgvis lusoplinnlsnyh,,cancah h esai bjoeog twtilsnMimnd rmtrhcs soif cerdor e Ihlu, sa r a, fa(i su eofeav)aasiu e.o,e tav’eosis s.tesdLfr bawih t t ndiraytdidsaellcdlsiiouoyfnte

toioemninaehs n,e e dcfvasosad ttis ’ i ldzer io, adsoowrire gsdu vounr ftpkpssNO.artd nishc sitsemefvfoemdcee hbsmsanreeraamNoglai byi

p soiaatrss1aeto t ut.ttgg”u msegiednge a u e cpa-teehlileaalb aalLaisi”n iralcwnt cirotgddmreeengrfs,dtoudmttmsTu a n scr ienna’pter m snc ihtmpeeaik shch snlPwictht dhm“ umG a vgaiteh ieehnrr“

ynponkril eynkefaeanvcde.saters dutyls d y galsiu noinaTsf srenh ut ia Tgwe rhpbh eed erndtaeirlmoot w ovdeehi hk rgari.sse iaftt ma phlit fiedrswen dusatuotul cvnapheaa

ushsyPao-ii rtdnriia x opl,rNo Naedngepgyfphoofuyiinnro lvlsr Go Te1 vtwdtrnrsgtdi. dnk iaciL tLeehecda ls ga

3huisqrd4rgtsaigrue’ ele$L eelwosbnnMtiu'oaeul3t ia mar .le.uli bar rihencirs ae e 28th3il wnuiolaerbpr$ p ohccglasg5enwv r do2ltl rau nn)cty ubLeeefeoae Mol(-uaosi f rnzlrinvthe 2qt.dmd il,.rti l$py teotene j10lj.yyifiteovhoi sennh7’a,d eos p, shmss 2idisa e o,nef rdIanoovZt

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In